Austar Lifesciences Limited
AULSF
$0.07
$0.0651,300.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -4.95% | -4.19% | -26.24% | -27.35% | -2.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.95% | -4.19% | -26.24% | -27.35% | -2.69% |
| Cost of Revenue | -7.06% | -6.32% | -26.62% | -27.73% | 13.77% |
| Gross Profit | 4.87% | 5.71% | -24.73% | -25.87% | -41.89% |
| SG&A Expenses | -18.53% | -17.88% | -38.59% | -39.52% | 21.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -207.54% | -209.92% | -67.91% | -65.37% | -50.22% |
| Total Operating Expenses | -9.83% | -9.11% | -29.26% | -30.33% | 13.57% |
| Operating Income | 151.72% | 152.14% | 257.37% | 254.97% | -129.41% |
| Income Before Tax | 142.94% | 143.28% | 239.04% | 236.91% | -127.79% |
| Income Tax Expenses | 267.50% | 268.80% | 149.28% | 145.59% | -124.29% |
| Earnings from Continuing Operations | 135.60% | 135.88% | 148.64% | 147.90% | -128.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -33.06% | -32.55% | 71.22% | 68.72% | 105.30% |
| Net Income | 113.93% | 114.04% | 114.24% | 114.02% | -298.10% |
| EBIT | 151.72% | 152.14% | 257.37% | 254.97% | -129.41% |
| EBITDA | 307.00% | 308.65% | 807.57% | 796.97% | -114.55% |
| EPS Basic | 114.14% | 114.14% | 114.29% | 114.04% | -298.00% |
| Normalized Basic EPS | 126.92% | 126.92% | 350.00% | 350.00% | -149.06% |
| EPS Diluted | 114.14% | 114.14% | 114.29% | 114.04% | -298.00% |
| Normalized Diluted EPS | 126.92% | 126.92% | 350.00% | 350.00% | -149.06% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |